Abstract
BackgroundImmune checkpoint inhibitors (ICI) generate T-cell mediated anti-tumor responses that are effective across numerous malignancies, but their use is frequently complicated by immune-related adverse events (irAEs). irAEs may lead to...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have